XBIO (Xenetic Biosciences) Short Percentage of Float


XBIO Xenetic Biosciences Inc XBIO
84 GF Score
Price $2.83
GF Value $4.19
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Xenetic Biosciences Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

XBIO vs ACXP, SILO, GOVX: Short Percentage of Float Comparison

For the Biotechnology subindustry, Xenetic Biosciences's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xenetic Biosciences Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Xenetic Biosciences's Short Percentage of Float falls into.


XBIO
84GF Score
Xenetic Biosciences Inc XBIO
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Xenetic Biosciences (XBIO) Overvalued in 2026?

Based on GuruFocus' analysis, Xenetic Biosciences stock appears to be undervalued. The current stock price of $2.83 is trading 32.5% below its estimated GF Value™ of $4.19. GuruFocus considers Xenetic Biosciences to be Possible Value Trap.

Key valuation signals for XBIO:

  • Short Percentage of Float:
  • GF Value™: $4.19 vs. price of $2.83 (32.5% below fair value)
  • GF Score™: 84/100 with 2 warning signs

No single metric tells the full story. See the XBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xenetic Biosciences Business Description

Address 945 Concord Street, Framingham, MA, USA, 01701
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
84GF Score

Get the complete analysis for XBIO

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.83
Price
$4.19
GF Value